Loading…
← CockpitCompetitor Analysis › NIOX.L NIOX Group PlcOpen in the cockpit ↗

NIOX Group PlcNIOX.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Medical/Nursing Services
Momentum weak 24
Mkt cap
$325M
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$1.20M
20-day average traded
Fwd P/E
19.8×
forward earnings
ROIC−WACC
+8.7 pp
WACC 6.9%
Hurdle
-12 pp
Req g minus delivered
Next earnings
125 days
23 Mar 2027
Close · GBP£61.00
1D+1.3%
1W-4.1%
1M-11.6%
3M-11.3%
6M+3.0%
YTD-8.1%
1Y-14.1%
ATR %5.5%
52w lowhigh23.8% off high

What NIOX does

Employees: 97

NIOX at a glance

Size NIOX (NIOX.L) is a United Kingdom Health Care company (Medical/Nursing Services) with a market value of $325M, the 346th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £61.00 on 18 Nov 2026.

Performance Over six months the shares gained 3.0%, against -4.0% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 3.3% over the last twelve months (peer median +6.0%); the operating margin is 21.9% (peer median 8.0%).

Valuation It trades at 19.8× forward earnings against a peer median of 16.9× (5th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.7 points above its cost of capital (6.9% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026NIOX.L 103Peer median 96
Six months, rebased to 100: NIOX against the median of its 20 peers (local-currency closes).

NIOX financials

Reported figures in GBP; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£47.5M£48.7M£41.8M£36.8M£31.3M
Revenue growth—+17%+14%+18%—
Gross profit£28.7M£29.6M£26.0M£22.1M£17.6M
EBITDA£14.7M£14.8M£11.9M£9.00M£6.40M
Net income£7.00M£7.00M£3.70M£10.7M£16.1M
Free cash flow£12.5M£15.6M£18.0M£12.1M£6.70M
Capital expenditure£1.00M£1.50M£1.00M£300,000£100,000
Total debtn/a£1.00M£1.50M£1.10M£1.00M

Quarterly statements and history in the cockpit →

NIOX competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300642AUNA3218AYUPADRAGARWQM129860JSLLIDXACLSRTA127120301060DNAWELLFLGTNEPHROPLUSGMRSNIOX.L6-month return →1-month return →
Up and to the right = strong over both horizons. NIOX is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×AUNA3218M129860JSLLIDXACLSRTAWELLNEPHROPLUSGMRSNIOX.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NIOX is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%STLN300642AUNA3218AYUPADRAGARWQM129860JSLLACL301060WELLNEPHROPLUSGMRS1951NIOX.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. NIOX is the large dot.

NIOX competitors and peer comparison

How NIOX compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NIOX against its 20 peers (data as of 18 Nov 2026)
MeasureNIOX.LPeer medianRank in peer set
1-month return-11.6%-6.8%10th lowest of 21
6-month return+3.0%-4.0%7th highest of 20
Distance from 52-week high-23.8%-30.8%9th highest of 21
Revenue growth (TTM)+3.3%+6.0%8th lowest of 21
Operating margin21.9%8.0%3rd highest of 21
Forward P/E19.8×16.9×5th most expensive of 13
Growth the price implies (Req g, 7 yrs)3.4%6.6%6th least demanding of 17
Growth delivered (Del g)+15.3%+16.6%8th lowest of 17
Hurdle (Req g minus delivered)-11.9 pp-12.8 pp9th least demanding of 17
ROIC minus cost of capital+8.7 pp-2.5 pp5th highest of 20
EV / EBITDA15.7×8.8×3rd most expensive of 13
Net debt / EBITDA-1.1×1.6×4th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are NIOX's closest peers?
The cockpit's peer set: Oncology Institute (STLN), Tellgen (300642.SZ), Auna (AUNA), Universal Vision Biotechnology (3218.TWO), Australian Unity Ltd Pref (AYUPA.AX), Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS), M1 Kliniken (M12.DE), ADICON (9860.HK).
Is NIOX expensive compared with its peers?
On forward p/e it trades at 19.8× against a peer median of 16.9×, 5th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has NIOX stock performed?
Over six months to 18 Nov 2026 the shares returned +3.0% against -4.0% for the median peer; over one year -14.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.